Artificial Intelligence-Driven Formulation Development

Parmar Jhanvi; Juhi Pandya; Archana Kaushik; Rashmi Rajeghorpade; Satyajit Sahoo; Sapna Desai; D.B. Meshram

doi:10.5281/zenodo.22706939

Review Paper | Open Access
Volume 04 | Issue 09 | Article Id IJPS/260409041

Artificial Intelligence-Driven Formulation Development
Parmar Jhanvi* ¹ Juhi Pandya ¹ Archana Kaushik ² Rashmi Rajeghorpade ² Satyajit Sahoo ³ Sapna Desai ³ D.B. Meshram ⁴
^1,2,3,4 Pioneer Pharmacy College, Sayajipura Vadodara-GTU

Abstract

Artificial Intelligence (AI) is becoming an important decision-support technology in pharmaceutical formulation development. Conventional formulation work often relies on repeated experiments to identify suitable compositions and processing conditions, which can require substantial time, materials, and specialist effort. Machine Learning (ML), Deep Learning (DL), Artificial Neural Networks (ANNs), and knowledge-based systems can learn from formulation data, predict product performance, and help prioritize experiments. Current applications include preformulation, excipient selection, tablet and controlled-release development, nanoparticle and liposomal systems, stability assessment, Quality by Design (QbD), Process Analytical Technology (PAT), and personalized dosage forms. AI can also support process monitoring and more efficient development strategies. However, practical implementation depends on data quality, appropriate validation, model interpretability, regulatory expectations, and continued human oversight. The most useful role of AI is therefore complementary: it can extend the analytical capacity of formulation scientists while leaving scientific interpretation and final development decisions under expert control.

Keywords

Artificial Intelligence; Machine Learning; Pharmaceutical Formulation; Quality by Design; Drug Delivery

Introduction

The pharmaceutical industry continually seeks safer and more effective medicines while reducing development time, cost, and experimental burden. Traditional formulation development relies heavily on laboratory trials and the experience of formulation scientists. Because many variables must be optimized simultaneously, repeated trial-and-error experiments can become labor-intensive and resource intensive.¹

Recent advances in Artificial Intelligence (AI) have introduced a data-driven approach to this process. AI systems can examine large experimental datasets, identify relationships among formulation variables, and provide predictions before a new formulation is manufactured. This does not remove the need for laboratory work; instead, it can help scientists decide which experiments are most informative and which formulation regions deserve closer investigation.²

The growing availability of pharmaceutical databases, computing resources, and cloud-based platforms has encouraged wider use of machine-learning methods. Historical data can be used to estimate properties such as dissolution, stability, excipient performance, and manufacturing outcomes.³ AI also complements Quality by Design (QbD) by helping researchers examine relationships among Critical Material Attributes (CMAs), Critical Process Parameters (CPPs), and Critical Quality Attributes (CQAs).⁴

AI is now being investigated across conventional and advanced dosage forms, including tablets, sustained-release systems, nanoparticles, liposomes, liquid formulations, and other delivery platforms.^5˒6 At the same time, issues involving data quality, validation, interpretability, regulatory acceptance, and implementation remain important barriers to routine industrial adoption.⁷

2. Fundamentals of Artificial Intelligence

Artificial Intelligence refers broadly to computer systems that perform tasks associated with learning, reasoning, prediction, or decision-making.⁸ In formulation research, AI is mainly used to analyze experimental information, predict product behavior, optimize variables, and reduce unnecessary experimentation.⁹

The main approaches discussed in pharmaceutical formulation include Machine Learning, Deep Learning, Artificial Neural Networks, and expert systems. ML and DL are especially useful when several formulation and process variables interact and the underlying relationships are difficult to describe with simple rules.¹⁰

2.1 Machine Learning (ML)

Machine Learning is a branch of AI in which algorithms learn patterns from existing data and use those patterns to make predictions for new observations.¹¹ In formulation development, ML can be used to estimate dissolution, stability, excipient effects, and other quality-related outcomes from previous experiments.¹²

Supervised learning uses labelled observations to predict a defined outcome; unsupervised learning searches for patterns or groups without a predefined target; and reinforcement learning improves decisions through feedback.¹¹ The choice of method should reflect the formulation question, the available data, and the level of validation required.

Figure 1-Overview of the role of machine learning in pharmaceutical development.^{1,3,5˒6, 11-18}

2.2 Deep Learning (DL)

Deep Learning uses multilayer neural networks to represent complex and high-dimensional relationships. Compared with conventional ML, DL can learn useful features from complex inputs with less manual feature engineering.¹³ In pharmaceutical formulation, applications include prediction of stability and dissolution, particle characteristics, CQAs, image-based inspection, and advanced drug-delivery performance.¹⁴

Deep-learning models generally need more data and computational resources than simpler ML approaches. Their value is greatest when the dataset and problem are sufficiently complex to justify the additional modelling effort. High predictive performance should therefore be considered together with validation and interpretability rather than as the only measure of model quality.¹⁵

Table 1. Comparison of Machine Learning and Deep Learning.^11,13–15

Feature	Machine Learning	Deep Learning
Data requirement	Moderate	Large
Human feature selection	Usually required	Often automated
Training time	Shorter	Longer
Typical formulation use	Formulation optimization, Dissolution prediction	Stability prediction, image analysis, advanced drug delivery

2.3 Artificial Neural Networks (ANNs)

Artificial Neural Networks are computational models inspired by interconnected biological neurons. They can learn nonlinear relationships between multiple formulation inputs and product characteristics.¹⁶ This feature is useful when several material and process variables influence the same quality attribute at the same time.¹⁷

ANN-based approaches have been used to predict drug-release profiles, optimize tablet formulations, estimate nanoparticle size, assess stability, and optimize manufacturing conditions.¹⁸ When validated properly, these models can help reduce experimental workload and focus laboratory effort on promising formulations.

2.4 Expert Systems

Expert systems use a knowledge base and predefined rules to support decisions. Unlike many ML models, they do not automatically learn from new observations; instead, they apply structured knowledge supplied by experts.¹⁹ In formulation work, such systems can assist with excipient selection, identification of formulation problems, process decisions, and quality-risk assessment.²⁰

2.5 Why AI Is Important in Formulation Development

Modern formulations involve drug properties, excipient concentrations, manufacturing methods, and processing conditions that may interact in complex ways. AI can rapidly analyze experimental datasets, identify influential variables, estimate formulation performance, and help prioritize experiments.^21˒22 The practical benefit is not simply faster computation; it is the ability to examine a larger experimental decision space before committing resources to laboratory trials.

3. AI in Pharmaceutical Formulation Development

AI is being explored across the formulation workflow, from preformulation through manufacturing. Data-driven models can be used to predict product behavior and optimize variables before extensive experimental testing.^23˒24 Major applications include preformulation, excipient selection, tablet and capsule development, controlled-release systems, nanotechnology, stability prediction, QbD, PAT, and liquid dosage forms.

3.1 AI in Preformulation Studies

Preformulation establishes the physicochemical foundation for dosage-form design. Important properties include solubility, stability, particle size, polymorphism, and drug–excipient compatibility.²⁵ AI can analyze earlier experiments and estimate these properties before large experimental campaigns are started. Applications include solubility prediction, compatibility assessment, stability estimation, polymorph prediction, and selection of suitable dosage forms.²⁶

Figure 2. AI-assisted preformulation workflow for pharmaceutical product development.^25,26

3.2 AI in Excipient Selection

Excipients influence stability, dissolution, manufacturability, and patient acceptability. Traditionally, selection has depended substantially on formulation experience and experimental screening. AI can compare previous formulation data and identify promising excipient combinations.²⁷ This can support faster screening, improved formulation stability, better release characteristics, and fewer unsuccessful development cycles.²⁸

3.3 AI in Tablet Formulation Development

Tablets remain widely used because of their convenience and stability. Their development requires coordinated selection of excipients and manufacturing variables such as granulation method, compression force, and coating conditions.²⁹ ML models can use previous batches to predict tablet characteristics and in-vitro performance, supporting formulation optimization.³⁰ Recent work has also examined prediction of disintegration-related parameters for fast-disintegrating tablets.³¹

Potential benefits include optimization of excipient concentration, prediction of dissolution behavior, improved consistency, shorter development timelines, and lower experimental workload.

3.4 AI in Controlled-Release Formulations

Controlled-release systems are designed to deliver drug gradually over an extended period. Their development involves optimization of polymers, drug concentration, and processing conditions.³² AI models can learn relationships between these variables and release profiles, allowing researchers to screen promising formulations before performing a large number of experiments.³³ Applications include polymer selection, matrix-tablet optimization, extended-release design, and process optimization.

3.5AI in Nanoparticle Formulation

Nanoparticle systems can improve delivery, solubility, bioavailability, and targeting, but their properties are strongly influenced by formulation and process variables.³⁴ AI models can predict particle size, entrapment efficiency, zeta potential, drug loading, and release behavior.³⁵ Recent formulation research further supports the use of ML for nanoparticulate design, optimization, and characterization.³⁴

3.6 AI in Liposomal Drug Delivery

Liposomes are phospholipid-based vesicles whose performance depends on lipid composition, cholesterol content, vesicle size, and preparation conditions.³⁶ Machine-learning methods can help estimate how these variables influence liposomal characteristics and can support optimization of lipid composition, entrapment efficiency, stability, release, and scale-up.³⁷ Recent work has also considered ML for lipid nanoparticle formulation and process development.³⁸

3.7 AI in Stability Prediction

Stability testing is essential for estimating shelf life and storage conditions, but conventional studies require long observation periods under multiple environmental conditions.³⁹ AI can learn from historical stability data and identify patterns associated with degradation.⁴⁰ Potential uses include shelf-life estimation, moisture sensitivity analysis, thermal stability prediction, photostability assessment, and packaging decisions. AI predictions should complement, rather than replace, conventional stability studies.

3.8 AI in Quality by Design (QbD)

QbD aims to build quality into a pharmaceutical product and process through systematic understanding of material and process relationships.⁴¹ AI can accelerate this analysis by examining large datasets and identifying variables that have important effects on product quality. ML can support assessment of relationships among CMAs, CPPs, and CQAs, strengthening formulation optimization and risk assessment.⁴²

3.9 AI in Process Analytical Technology (PAT)

PAT supports timely measurement and control of pharmaceutical processes and quality attributes.⁴³ When AI is combined with PAT data, ML models can assist with process monitoring, prediction, anomaly detection, and optimization.⁴⁴ Applications include blend-uniformity monitoring, granulation endpoint detection, tablet compression, coating, and continuous manufacturing.⁴⁵ Recent work in oral solid-dosage manufacturing also emphasizes predictive modelling and real-time process optimization.⁴⁶

3.10 AI in Personalized Medicine

Personalized medicine seeks to tailor treatment to individual patient requirements. Patient characteristics can influence drug response and dose requirements.⁴⁷ AI can support development of individualized dosage forms, personalized combinations, AI-assisted 3D-printed medicines, and precision delivery systems.^48˒49 These applications may eventually connect formulation design with patient-specific needs more closely than conventional one-size-fits-all dosage forms.

4. Advantages of AI in Pharmaceutical Formulation Development

AI can accelerate formulation development by rapidly examining experimental data and predicting performance, potentially reducing the number of iterative laboratory trials.^50˒51 It can also estimate dissolution, stability, release, and other quality attributes and help identify influential variables.

Reduced experimentation can lower material consumption, laboratory workload, and development cost.⁵² At the same time, data-driven optimization can support reproducibility and more consistent product quality.⁵³ AI may also encourage exploration of novel formulation strategies and advanced drug-delivery systems.⁵⁴

5. Challenges and Limitations of AI in Pharmaceutical Formulation Development

Despite its potential, successful AI implementation depends on reliable data, appropriate model selection, sufficient computational resources, and rigorous validation.⁷

5.1 Data Availability and Quality

AI models need accurate, sufficiently representative, and well-organized training data. Pharmaceutical datasets may be small, incomplete, heterogeneous, or generated under different laboratory conditions. Such differences can limit model generalization and may introduce misleading relationships.³

5.2 Regulatory Challenges

Pharmaceutical AI applications require appropriate validation, documentation, transparency, and scientific justification before routine use.⁵⁵ Regulatory expectations become particularly important when a model influences product quality or manufacturing decisions.

5.3 Model Interpretability

Complex models, particularly some deep-learning systems, can behave like black boxes.⁵⁶ Limited transparency can reduce confidence in predictions and make scientific review more difficult. Explainable-AI approaches can help researchers understand influential inputs, but explanations should still be interpreted within the limitations of the model and dataset.

5.4 High Initial Investment

Implementation may require software, computational infrastructure, data-management systems, and personnel with both pharmaceutical and data-science expertise. These requirements can increase the initial investment, especially for organizations with limited digital infrastructure.

5.5 Dependence on Human Expertise

AI can process information and generate predictions, but formulation scientists remain essential for experimental design, interpretation, risk assessment, and final development decisions.¹⁰ Overfitting is another concern: a model may perform well on training data but fail on genuinely new formulations. Independent validation and appropriate test datasets are therefore necessary.

6. Future Perspectives

Future formulation programs may increasingly combine AI with digital twins, explainable AI, cloud computing, robotics, automated experimentation, and continuous manufacturing.⁵⁷ Digital-twin concepts may allow virtual representation of development or manufacturing systems, although their practical value will depend on data quality and model validation.⁵⁸

Self-driving laboratories are another emerging direction. In such workflows, an AI system can propose experiments, laboratory automation can execute them, and the results can be fed back to the model for the next cycle.⁵⁷ The most realistic near-term role is not complete autonomy but a tighter learning loop between computational prediction and experimental evidence.

Recent formulation-focused work also points toward broader AI support for dosage design, precision delivery, and personalized manufacturing.^60˒62˒66 Good implementation practice requires clear problem definition, curated datasets, external validation, uncertainty assessment, transparent documentation, and human review.^61˒64˒65

7. CONCLUSION

Artificial Intelligence is becoming a useful complementary technology in pharmaceutical formulation development. ML, DL, ANNs, and expert systems can support prediction, optimization, and decision-making across preformulation, excipient selection, tablets, controlled release, nanoparticles, liposomes, stability, QbD, PAT, and personalized delivery.

The value of AI lies in extending the analytical capacity of formulation teams rather than replacing scientific expertise. Data quality, model interpretability, validation, regulatory acceptance, and computational infrastructure remain important limitations.

With well-curated datasets and appropriate human oversight, AI can help formulation scientists explore more options, reduce unnecessary experimentation, and make development decisions more efficiently. Future progress will depend on collaboration among formulation scientists, data scientists, manufacturing teams, and regulatory stakeholders.

Declarations Conflict of Interest

The author declares that there is no conflict of interest related to this article.

Funding

No specific funding was received for the preparation of this article.

Author Contribution

The author was responsible for the conception of the review, literature organization, drafting, critical revision, and final approval of the manuscript.

Originality / Non-Submission Statement

This manuscript is an original review prepared for academic submission. It has not been submitted simultaneously to another journal or publication venue.

REFERENCES

Bannigan P, Aldeghi M, Bao Z, et al. Machine learning directed drug formulation development. Adv Drug Deliv Rev. 2021;175:113806. doi: 10.1016/j.addr.2021.05.016.
Bannigan P, Aldeghi M, Bao Z, et al. Machine learning directed drug formulation development. Adv Drug Deliv Rev. 2021;175:113806. doi: 10.1016/j.addr.2021.05.016.
Bannigan P, Aldeghi M, Bao Z, et al. Machine learning directed drug formulation development. Adv Drug Deliv Rev. 2021;175:113806. doi: 10.1016/j.addr.2021.05.016.
Puranik A, Dandekar P, Jain R. Exploring the potential of machine learning for more efficient development and production of biopharmaceuticals. Biotechnol Prog. 2022;38(6):e3291. doi: 10.1002/btpr.3291.
Jiang J, Ma X, Ouyang D, et al. Emerging artificial intelligence technologies used in the development of solid dosage forms. Pharmaceutics. 2022;14(11):2257. doi: 10.3390/pharmaceutics14112257.
Bao Z, Bufton J, Hickman RJ, et al. Revolutionizing drug formulation development: the increasing impact of machine learning. Adv Drug Deliv Rev. 2023;202:115108. doi: 10.1016/j.addr.2023.115108.
Shinde A, Mhaismale H, Pawar P, et al. Generative artificial intelligence and large language models in pharmaceutical formulation and personalized pharmacy: a review of opportunities, technical constraints, and regulatory readiness. Drug Dev Ind Pharm. 2026;52(5):793-807. doi: 10.1080/03639045.2026.2649846.
Russell S, Norvig P. Artificial Intelligence: A Modern Approach. 4th ed. Pearson; 2021.
Bao Z, Bufton J, Hickman RJ, et al. Revolutionizing drug formulation development: the increasing impact of machine learning. Adv Drug Deliv Rev. 2023;202:115108. doi: 10.1016/j.addr.2023.115108.
Noorain, Srivastava V, Parveen B, et al. Artificial intelligence in drug formulation and development: applications and future prospects. Curr Pharm Des. 2023;24(9):622-634. doi: 10.2174/0113892002265786230921062205.
Goodfellow I, Bengio Y, Courville A. Deep Learning. Cambridge, MA: MIT Press; 2016.
Bannigan P, Aldeghi M, Bao Z, et al. Machine learning directed drug formulation development. Adv Drug Deliv Rev. 2021;175:113806. doi: 10.1016/j.addr.2021.05.016.
LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015;521(7553):436-444. doi: 10.1038/nature14539.
Wang S, Di J, Wang D, et al. State-of-the-art review of artificial neural networks to predict, characterize and optimize pharmaceutical formulation. Pharmaceutics. 2022;14(1):183. doi: 10.3390/pharmaceutics14010183.
Singh S, De A. The paradigm shift in therapeutics: a comprehensive review of artificial intelligence in drug delivery systems. SC Pharm. 2026;3:645-653. doi: 10.1039/D5PM00235D.
Takayama K, Fujikawa M, Nagai T. Artificial neural network as a novel method to optimize pharmaceutical formulations. Pharm Res. 1999;16(1):1-6. doi: 10.1023/A:1011986823850.
Takayama K, Fujikawa M, Nagai T. Artificial neural network as a novel method to optimize pharmaceutical formulations. Pharm Res. 1999;16(1):1-6. doi: 10.1023/A:1011986823850.
Takayama K, Fujikawa M, Obata Y, Morishita M. Neural network based optimization of drug formulations. Adv Drug Deliv Rev. 2003;55(9):1217-1231. doi: 10.1016/S0169-409X(03)00120-0.
Rowe RC, Roberts RJ. Artificial intelligence in pharmaceutical product formulation: knowledge-based and expert systems. J Pharm Pharmacol. 1998;50(4):S1-S6.
Wang N, Sun H, Dong J, Ouyang D. PharmDE: A new expert system for drug-excipient compatibility evaluation. Int J Pharm. 2021;607:120962. doi: 10.1016/j.ijpharm.2021.120962.
Bao Z, Bufton J, Hickman RJ, et al. Revolutionizing drug formulation development: the increasing impact of machine learning. Adv Drug Deliv Rev. 2023;202:115108. doi: 10.1016/j.addr.2023.115108.
Bao Z, Bufton J, Hickman RJ, et al. Revolutionizing drug formulation development: the increasing impact of machine learning. Adv Drug Deliv Rev. 2023;202:115108. doi: 10.1016/j.addr.2023.115108.
Bannigan P, Aldeghi M, Bao Z, et al. Machine learning directed drug formulation development. Adv Drug Deliv Rev. 2021;175:113806. doi: 10.1016/j.addr.2021.05.016.
Bao Z, Bufton J, Hickman RJ, et al. Revolutionizing drug formulation development: the increasing impact of machine learning. Adv Drug Deliv Rev. 2023;202:115108. doi: 10.1016/j.addr.2023.115108.
Noorain, Srivastava V, Parveen B, et al. Artificial intelligence in drug formulation and development: applications and future prospects. Curr Pharm Des. 2023;24(9):622-634. doi: 10.2174/0113892002265786230921062205.
Nithyanantham D, Nair A, Nayak UV. Leveraging artificial intelligence for advancements in liquid dosage formulations in the pharmaceutical industry. Ther Innov Regul Sci. 2025;59:1004-1031. doi: 10.1007/s43441-025-00823-w.
Patel S, Patel M, Kulkarni M, Patel MS. DE-INTERAST: a machine-learning-based predictive tool for drug-excipient interaction study during product development. Int J Pharm. 2023;631:123839.
Hang NT, Long NT, Bui NB, Chien NN, Van Phuong N. Towards safer and efficient formulations: machine learning approaches to predict drug-excipient compatibility. Int J Pharm. 2024;859:123884. doi: 10.1016/j.ijpharm.2024.123884.
Aulton ME, Taylor KMG, editors. Aulton's Pharmaceutics: The Design and Manufacture of Medicines. 5th ed. Elsevier; 2018.
Gupta D, Biswas AA, Sahu R, et al. Advancing pharmaceutical intelligence via computationally prognosticating the in vitro parameters of fast disintegration tablets using machine learning models. Eur J Pharm Biopharm. 2024;204:114508. doi: 10.1016/j.ejpb.2024.114508.
Moin A, Fatima F, Alqahtani F, et al. Development of machine learning models for estimation of disintegration time on fast-disintegrating tablets. Eur J Pharm Sci. 2025;211:107141. doi: 10.1016/j.ejps.2025.107141.
Sun Y, Peng Y, Chen Y, Shukla AJ. Application of artificial neural networks in the design of controlled release drug delivery systems. Adv Drug Deliv Rev. 2003;55(9):1201-1215. doi: 10.1016/S0169-409X(03)00119-4.
Protopapa C, Siamidi A, Eneli AA, et al. Machine learning predicts drug release profiles and kinetic parameters based on tablets' formulations. AAPS J. 2025;27(5):124. doi: 10.1208/s12248-025-01101-1.
Shen C, Zhang M, Lu M, et al. Machine learning empowered formulation design, optimization and characterization of nanoparticulate drug delivery systems: current applications, challenges, and future perspectives. Acta Pharm Sin B. 2026;16(2):665-685. doi: 10.1016/j.apsb.2025.12.011.
Wang Q, Liu Y, Li C, et al. Machine learning-enhanced nanoparticle design for precision cancer drug delivery. Adv Sci (Weinh). 2025;12(30):e2503138. doi: 10.1002/advs.202503138.
Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(2):12. doi: 10.3390/pharmaceutics9020012.
Matalqah S, Lafi Z, Mhaidat Q, et al. Applications of machine learning in liposomal formulation and development. Pharm Dev Technol. 2025;30(1):126-136. doi: 10.1080/10837450.2024.2448777.
Dorsey PJ, Lau CL, Chang TC, et al. Review of machine learning for lipid nanoparticle formulation and process development. J Pharm Sci. 2024;113(12):3413-3433. doi: 10.1016/j.xphs.2024.09.015.
Waterman KC. The application of the accelerated stability assessment program (ASAP) to quality by design (QbD) for drug product stability. AAPS PharmSciTech. 2011;12(3):932-937. doi: 10.1208/s12249-011-9663-9.
Grigoryan A, Helfrich S, Lequeux V, et al. Smart formulation: AI-driven web platform for optimization and stability prediction of compounded pharmaceuticals using KNIME. Pharmaceuticals. 2025;18(8):1240. doi: 10.3390/ph18081240.
International Council for Harmonisation. ICH Q8(R2): Pharmaceutical Development. ICH; 2009.
Chaurasia GK, Tiwari RK, Verma S. Application of Quality by Design as artificial intelligence in formulation for diabetes: a practical review. Recent Adv Drug Deliv Formul. 2026. doi: 10.2174/0126673878428147260531183116.
U.S. Food and Drug Administration. PAT: A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. Guidance for Industry. FDA; 2004.
Nagy B, Galata DL, Farkas A, et al. Application of artificial neural networks in the process analytical technology of pharmaceutical manufacturing: a review. AAPS J. 2022;24(4):74. doi: 10.1208/s12248-022-00706-0.
Nakka G, Gupta S, Reddy KK. Artificial intelligence in pharmaceutical manufacturing: applications, case studies, and GxP implementation considerations. J Pharm Sci. 2026;115(5):104240. doi: 10.1016/j.xphs.2026.104240.
Lou H, Lian B, Hageman MJ, et al. Applications of machine learning in solid oral dosage form development. J Pharm Sci. 2021;110(9):3150-3165. doi: 10.1016/j.xphs.2021.04.013.
Wicha SG, et al. Model-informed precision dosing: state of the art and future perspectives. Adv Drug Deliv Rev. 2024;215:115421. doi: 10.1016/j.addr.2024.115421.
Abdalla Y, Nandiraju LP, Yue H, et al. Artificial intelligence-enabled personalisation of oral drug delivery: from data-driven design to on-demand manufacturing. Adv Drug Deliv Rev. 2026;233:115855. doi: 10.1016/j.addr.2026.115855.
Kassa FM, Youssef SH, Song Y, Garg S. Use of computational intelligence in customizing drug release from 3D-printed products: a comprehensive review. Pharmaceutics. 2025;17(5):551. doi: 10.3390/pharmaceutics17050551.
Noorain, Srivastava V, Parveen B, et al. Artificial intelligence in drug formulation and development: applications and future prospects. Curr Drug Metab. 2023;24(9):622-634. doi: 10.2174/0113892002265786230921062205.
Bannigan P, Aldeghi M, Bao Z, et al. Machine learning directed drug formulation development. Adv Drug Deliv Rev. 2021;175:113806. doi: 10.1016/j.addr.2021.05.016.
Bao Z, Bufton J, Hickman RJ, et al. Revolutionizing drug formulation development: the increasing impact of machine learning. Adv Drug Deliv Rev. 2023;202:115108. doi: 10.1016/j.addr.2023.115108.
Wang S, Di J, Wang D, et al. State-of-the-art review of artificial neural networks to predict, characterize and optimize pharmaceutical formulation. Pharmaceutics. 2022;14(1):183. doi: 10.3390/pharmaceutics14010183.
Wang N, Dong J, Ouyang D. AI-directed formulation strategy design initiates rational drug development. J Control Release. 2025;378:619-636. doi: 10.1016/j.jconrel.2024.12.043.
U.S. Food and Drug Administration, Health Canada, Medicines and Healthcare products Regulatory Agency. Good Machine Learning Practice for Medical Device Development: Guiding Principles. 2021.
Qadri YA, Shaikh S, Ahmad K, et al. Explainable artificial intelligence: a perspective on drug discovery. Pharmaceutics. 2025;17(9):1119. doi: 10.3390/pharmaceutics17091119.
Bao Z, Bufton J, Hickman RJ, et al. Revolutionizing drug formulation development: the increasing impact of machine learning. Adv Drug Deliv Rev. 2023;202:115108. doi: 10.1016/j.addr.2023.115108.
Venkatapurapu SP, Clegg L, Nowojewski A, et al. Digital twins for accelerating drug discovery and development: opportunities and challenges. Drug Discov Today. 2026;31(2):104617. doi: 10.1016/j.drudis.2026.104617.
Ros H, Chan N, Cook MT, et al. Artificial intelligence and machine learning guided optimization in drug delivery. Adv Drug Deliv Rev. 2026;232:115781. doi: 10.1016/j.addr.2026.115781.
Murray JD, Lange JJ, Bennett-Lenane H, Holm R, Kuentz M, O'Dwyer PJ, Griffin BT. Advancing algorithmic drug product development: recommendations for machine learning approaches in drug formulation. Eur J Pharm Sci. 2023;191:106562. doi: 10.1016/j.ejps.2023.106562.
Gosavi AA, Nandgude TD, Mishra RK, Puri DB. Exploring the potential of artificial intelligence as a facilitating tool for formulation development in fluidized bed processor: a comprehensive review. AAPS PharmSciTech. 2024;25(5):111. doi: 10.1208/s12249-024-02816-8.
Shen C, Zhang M, Lu M, et al. Machine learning empowered formulation design, optimization and characterization of nanoparticulate drug delivery systems: current applications, challenges, and future perspectives. Acta Pharm Sin B. 2026;16(2):665-685. doi: 10.1016/j.apsb.2025.12.011.
Neugebauer P, Zettl M, Moser D, Poms J, Kuchler L, Sacher S. Process analytical technology in downstream-processing of drug substances: a review. Int J Pharm. 2024;661:124412. doi: 10.1016/j.ijpharm.2024.124412.
U.S. Food and Drug Administration, Health Canada, Medicines and Healthcare products Regulatory Agency. Transparency for Machine Learning-Enabled Medical Devices: Guiding Principles. 2024.
Joshi S, Sheth S. Artificial Intelligence in Pharmaceutical Formulation and Dosage Calculations. Pharmaceutics. 2025;17(11):1440. doi: 10.3390/pharmaceutics17111440.
Joshi S, Sheth S. Artificial Intelligence in Pharmaceutical Formulation and Dosage Calculations. Pharmaceutics. 2025;17(11):1440. doi: 10.3390/pharmaceutics17111440